Literature DB >> 6813004

Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.

A Vincent, J Newsom-Davis.   

Abstract

We have investigated anti-acetylcholine receptor (AChR) characteristics in three forms of generalized myasthenia gravis, which are distinguishable by their thymic pathology, age of onset, sex incidence and HLA antigen associations, and in restricted ocular myasthenia. Light chain, IgG subclass, avidity for denervated human AChR and reaction with various human and mammalian AChR preparations were examined in 9-12 patients from each group. Characteristics varied between individuals in each group but no significant differences were found in mean values between the three groups with generalized myasthenia. When antibody characteristics in ocular myasthenia were compared with those in generalized disease, however, differences were found particularly in relative reactivity with denervated, normal and ocular human AChR. The nature of the humoral response in ocular myasthenia thus differs from that in generalized myasthenia. The similarity in the humoral response between the three groups of generalized myasthenia suggests, on the other hand, that the distinguishing clinical features may reflect differing susceptibilities to diverse precipitating mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813004      PMCID: PMC1536506     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Oral corticosteroids in the treatment of ocular myasthenia gravis.

Authors:  K C Fischer; R J Schwartzman
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

Review 2.  Human immunoglobulins: classes, subclasses, genetic variants, and idiotypes.

Authors:  J B Natvig; H G Kunkel
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

3.  The determination of serum immunoglobulin concentrations on the basis of their light-chain antigenic properties.

Authors:  K Eickhoff; R Heipertz
Journal:  Clin Chim Acta       Date:  1977-07-15       Impact factor: 3.786

4.  alpha-Bungarotoxin and anti-acetylcholine receptor antibody binding to the human acetylcholine receptor.

Authors:  A Vincent; J Newsom-Davis
Journal:  Adv Cytopharmacol       Date:  1979

Review 5.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

Review 6.  Cold auto-agglutinins.

Authors:  M Harboe
Journal:  Vox Sang       Date:  1971-04       Impact factor: 2.144

7.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

8.  Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.

Authors:  A K Lefvert; K Bergström
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

9.  Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors.

Authors:  C B Weinberg; Z W Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

10.  Specificities of antibodies to acetylcholine receptors.

Authors:  J Lindstrom; M Campbell; B Nave
Journal:  Muscle Nerve       Date:  1978 Mar-Apr       Impact factor: 3.217

View more
  33 in total

Review 1.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 3.  Immunopathogenesis and treatment of myasthenia gravis.

Authors:  A I Levinson; B Zweiman; R P Lisak
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

4.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

5.  Anti-acetylcholine receptor idiotypes in myasthenia gravis analysed by rabbit anti-sera.

Authors:  B Lang; A J Roberts; A Vincent; J Newsom-Davis
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

6.  Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

Authors:  Crandall E Peeler; Lindsey B De Lott; Lina Nagia; Joao Lemos; Eric R Eggenberger; Wayne T Cornblath
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

7.  Myasthenia gravis: overlap with 'polyendocrine' autoimmunity.

Authors:  W A Scherbaum; F Schumm; B Maisch; C Müller; A Fateh-Moghadam; S H Flüchter; F J Seif; G F Bottazzo; P A Berg
Journal:  Klin Wochenschr       Date:  1983-05-16

Review 8.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

9.  [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis].

Authors:  I Kalies; F Heinz; W P Kaschka; K F Druschky; J R Kalden
Journal:  Klin Wochenschr       Date:  1984-04-16

10.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.

Authors:  A Vincent; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.